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INTRODUCTION
Advanced glycation end products (AGE) have been impli-
cated in the pathogenesis of many of the secondary compli-
cations of diabetes (1), especially vascular disease. The effects
of AGE may also be mediated through interaction with recep-
tors on endothelial, smooth muscle, mesangial, and inflam-
matory cells, among others (2). Increased serum AGE has
been shown to contribute to the accelerated vascular dys-
function associated with uremia and diabetes (3, 4). The for-
mation of AGE has been proposed to result in cross-linking
of collagen and distortion of subcelluar structures, causing
irreversible tissue damage in peripheral nerves, the macro
and microvasculature (5, 6). Prolonged exposure to the glu-
cose-based dialysis fluids, currently in use, results in produc-
tion and deposition of AGE in the subendothelial area of
the peritoneum, inducing microvascular changes similar to
those seen in diabetes, and eventually loss of peritoneal func-
tion.
Several studies have demonstrated the inhibition of AGE
formation. Aminoguanidine inhibits AGE formation and
protein cross-linking in vitro (7). Administration of amino-
guanidine to rats prevents diabetes-induced AGE formation
and cross-linking of arterial wall connective tissue protein
in vivo (8); Aminoguanidine also prevents the increased vas-
cular permeability in the aorta, skin, intestine, heart, vena
cava, and brain tissue after exogenous injection of AGE in
rats (9). However, aminoguanidine cannot cleave or remove
preformed tissue AGEs.
More recently, AGE cross-link breakers, such as N-phe-
nacylthiazolium bromide and alagebrium (4, 5-Dimethyl-
3-[2-oxo2-phenylethyl]-thiazolium chloride) have been report-
ed to reverse a number of diseases presumably due to cleav-
age of tissue AGEs (10-12). Alagebrium is a member of a
new generation of compounds developed for clinical investi-
gation. It is thought to cleave established AGE cross-links.
Alagebrium has been shown to reverse AGE-mediated vas-
cular stiffness in diabetic rats (12) and have improved arteri-
al compliance in aged humans (13). Many studies have report-
ed the effectiveness of alagebrium in a variety of models of
diabetic complications (14-16). 
Comparison of alagebrium and aminoguanidine, in a long-
term peritoneal dialysis animal model, has not been report-
ed. The present study was performed to evaluate, in a rat in
vivo model of peritoneal dialysis, the effects of alagebrium
and aminoguanidine on reversal of preformed peritoneal
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The Breakdown of Preformed Peritoneal Advanced Glycation End
Products by Intraperitoneal Alagebrium
It has been demonstrated that inhibitors of advanced glycation end products (AGE),
such as aminoguanidine, can suppress peritoneal AGE in rats on peritoneal dialy-
sis (PD). However, it is unknown whether late administration of a putative cross-
link breaker, alagebrium, could reverse peritoneal AGE. We therefore compared
alagebrium with aminoguanidine in their ability to reverse peritoneal AGE in rats
on PD. Male Sprague-Dawley rats were randomly divided into 3 groups: group I
dialyzed with 4.25% glucose solution for all exchanges; group II dialyzed with 4.25%
glucose solution containing aminoguanidine, and group III dialyzed with 4.25% glu-
cose solution containing alagebrium for last 8 weeks of 12-week dialysis period.
Dialysis exchanges were performed 2 times a day for 12 weeks. Immunohisto-
chemistry was performed using a monoclonal anti-AGE antibody. One-hour PET
was performed for comparison of transport characteristics. The immunolabelling of
AGE in peritoneal membrane was markedly decreased in the alagebrium group.
Consistent with this, the alagebrium group exhibited significantly higher D/Do glu-
cose and lower D/P urea, suggesting low peritoneal membrane transport. But there
were no significant differences between the control and the aminoguanidine group.
These results suggest that the alagebrium may be the optimal therapeutic approach,
compared with treatment with inhibitors of AGE formation, in rats on PD.
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teristics.
MATERIALS AND METHODS
The study was performed on 36 male Sprague-Dawley rats
weighing between 275 g and 300 g randomly divided into
three groups: group I (n=12), control rats were injected intra-
peritoneally with 4.25% glucose solution for 12 weeks; group
II (n=12), rats were intraperitoneally with 4.25% glucose
solution containing aminoguanidine (25 mg/kg) for the last
8 weeks of the 12 week; group III (n=12), rats were injected
intraperitoneally with 4.25% glucose solution containing
alagebrium (2 mg/kg) for the last 8 weeks of the 12 week
study.
Prior to completion of the study, 4 animals in group I, 1
animal in group II, and 2 animals in group III were eutha-
nized due to the development of peritonitis, leaving 29 ani-
mals for the analysis.
Intraperitoneal injection
The rats were anesthetized with ether prior to each intraperi-
toneal injection of dialysis solution. The abdominal wall was
shaved and cleaned with an antiseptic agent (Amukin
�, Amu-
china, Italy). Commercially available dialysis solution contain-
ing 4.25% glucose (Perisis
�, Boryung Pharma Company,
Korea) was injected (25 mL) into the peritoneal cavity using
a 20 gauge needle, twice a day at 07:00 and 19:00 hr, 7 days
a week for 12 weeks. Prophylactic antibiotics were adminis-
tered intraperitoneally with the solution; and were changed
every 3 days in the following sequence: gentamicin 8 mg/L;
ceftazidime 125 mg/L; and vancomycin 25 mg/L, respec-
tively.
Weight measurement
All animals were weighed at the time of arrival and at 3,
6, 9, and 12 weeks. The weights were recorded before the
morning intraperitoneal injection.
Peritoneal equilibrium test (PET) 
The peritoneal function was assessed at the 12th week by
a 1-hr PET using 1.5% glucose solution. A 1.5% glucose
solution was used for the overnight exchange preceding the
PET. At time 0, 25 mL of dialysis solution was administered
intraperitoneally. At 1 hr, the animal was anesthetized, and
a sample of dialysate was taken for measurement of urea nitro-
gen, creatinine, and glucose. Immediately thereafter, a blood
sample (2 mL) was taken by direct cardiac puncture for mea-
surement of urea nitrogen, creatinine, and glucose.
The peritoneal membrane transport rate was assessed by
dialysate-to-plasma ratio (D/P) of urea nitrogen and D/Do
glucose, where D is the glucose concentration in the dialysate
after the 1-hr dwell, and Do is the glucose concentration in
the dialysis solution before infusion into the peritoneal cavi-
ty. High levels of D/P urea nitrogen and low levels of D/Do
glucose indicate high transport.
Immunohistochemical analysis
All animals were humanely euthanized during the 12th
week, and specimens for immunostaining were obtained. Peri-
toneal tissues were taken from four locations: a loop of gut
with mesentery, abdominal wall, diaphragm, and the sur-
face of liver. Peritoneal sections (4 μ m thick) were cut from
paraffin blocks.
Immunostaining of AGE in peritoneal tissue sections was
conducted using the streptoavidin-biotinylated peroxydase
complex method. The sections were washed three times with
phosphate buffered saline (PBS). Endogenous peroxidase activ-
ity was blocked by incubating the sections with 0.3% H2O2
at room temperature for 30 min. The sections were washed
with PBS and incubated with normal goat serum in PBS at
room temperature for 2 hr. After the normal goat serum was
removed, the sections were incubated in a humid chamber
at room temperature overnight with anti-AGE mouse mon-
oclonal antibody (Dojindo Laboratories, Tokyo, Japan) dilut-
ed 100× in PBS. The sections were washed with PBS and
incubated with secondary antibody, biotinylated anti-mouse
Immunoglobulin G ([IgG] Vector Laboratories, Burlingame,
CA, U.S.A.), at room temperature for 1 hr. After washing three
times with PBS, the sections were incubated with streptoa-
vidin peroxidase complex (Vector Laboratories) at room tem-
perature for 30 min. After washing three times with PBS, the
peroxidase reaction was visualized by incubation with diamino-
benzidine for 15 min. After washing with PBS, the slides were
counterstained with hematoxylin. Control staining without
primary antibody was performed (2 sections in each group)
to confirm specificity of the reaction.
The slides were independently read by five separate exam-
iners in a blinded fashion and staining intensity was graded
semi-quantitatively from 0 to 3, where 0 represented no stain-
ing, 1 represented weak staining, 2 represented moderate
staining, and 3 represented strong staining.
Statistical analysis
Data are presented as mean±standard deviation (SD). Sta-
tistical analysis of values at various time points among the
groups were assessed by one-way analysis of variance (ANO-
VA), with Dunn’s method for multiple comparisons, using
the software SigmaStat 2.0 for Window (SPSS Inc., Chica-
go, IL, U.S.A.). Differences were considered significant at
p<0.05.
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Immunostaining of AGE in peritoneal membrane
Immunostaining showed that AGEs accumulation was
weak in the alagebrium group (Fig. 1C, 2C). For the ami-
noguanidine group, the intensity of staining of the mesothe-
lial layers ranged from moderate to strong (Fig. 1B). Stain-
ing of the vascular wall was weakly to moderately positive
in this group (Fig. 2B). In the control group, the mesothe-
lial layers had a consistent staining pattern ranging from
moderate to strong (Fig. 1A). Staining of the vascular wall
was moderately to strongly positive in this group (Fig. 2A).
Fig. 3 shows the scores for AGEs staining by the respective
groups. The immunostaining grade was lowest in the alage-
brium treated group and highest in the control group. Sig-
nificant differences were observed in comparisons of the alage-
brium group (1.07±0.18) with the aminoguanidine group
(2.09±0.45, p<0.05) and with the control group (2.14±
0.32, p<0.05).
Peritoneal equilibration test
Table 1 shows D/Do glucose, D/P urea nitrogen and D/P
creatinine in the respective groups. Significant differences
in D/Do were seen in comparisons of the alagebrium group
(0.51±0.03) with the aminoguanidine group (0.44±0.07,
p<0.05) and with the control group (0.40±0.07, p<0.05).
For D/P urea nitrogen, differences were noted in comparisons
of the alagebrium group (0.78±0.05) with the aminoguani-
dine treated group (0.87±0.10, p<0.05) and with the con-
trol group (0.89±0.08, p<0.05). For the D/P creatinine,
differences were observed in the comparisons of the alage-
brium group (0.78±0.17) with the control group (0.85±
0.13, p<0.05).
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Fig. 1. Immunostaining for advanced glycation end products in
the peritoneal mesothelial cell. The mesothelial cells of group I (A)
and group II (B) show moderate to strong expression. However,
the mesothelial cells of group III (C) show weak expression.
A B
C
Data are presented as mean±standard deviation (SD). 
Group I, rats dialyzed with glucose solution; Group II, rats dialyzed with
glucose solution containing aminoguanidine; Group III, rats dialyzed
with glucose solution containing alagebrium.
*p<0.05 Control group vs. alagebrium group; 
� p<0.05 Aminoguanidine
group vs. alagebrium group.
Group I
(n=8)
Group II
(n=11)
Group III 
(n=10)
D/D0 Glucose 0.42±0.07 0.44±0.07 0.51±0.07*,�
D/P Urea nitrogen 0.89±0.08 0.87±0.1 0.78±0.05*
D/P Creatinine 0.85±0.13 0.83±0.09 0.78±0.17*
Table 1. Peritoneal transport of glucose, urea nitrogen, and
creatinine Body weight
Table 2 shows changes in weight over time. The mean
baseline weight of the rats was approximately 257 g. Weight
increased in all groups over the period of study. However,
there were no significant differences between groups.
DISCUSSION
Long-term peritoneal dialysis, using high glucose solutions,
results in increased peritoneal AGE accumulation leading
to increased peritoneal permeability to small solutes, such as
glucose, urea and creatinine. The results of this study show
that alagebrium reversed preformed peritoneal AGE accu-
mulation and improved peritoneal permeability. However,
treatment with aminoguanidine did not reverse established
peritoneal AGE accumulation. 
Peritoneal accumulation of AGE has been reported in non-
diabetic patients on long-term peritoneal dialysis (17, 18) and
has been related to increased peritoneal permeability in long-
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Fig. 2. Immunostaining for advanced glycation end products in
the peritoneal vascular wall. The vessels of group I (A) and group
II (B) show moderate to strong expression. However, the vessels
of group III (C) show weak expression.
A B
C
Data are presented as mean±standard deviation (SD).
Group I, rats dialyzed with glucose solution; Group II, rats dialyzed with
glucose solution containing aminoguanidine; Group III, rats dialyzed
with glucose solution containing alagebrium.
1 week 12 week 6 week 9 week 3 week Group
I 263.7±11.9 301.0±19.6 322.5±24.9 353.8±15.1 366.3±19.2
II 255.5±8.2 299.1±15.8 317.3±21.5 351.0±22.6 357.3±25.7
III 252.0±17.5 307.0±20.6 333.0±25.0 359.0±37.3 385.0±38.7
Table 2. Changes in body weight (grams)
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Fig. 3. Semiquantitative scoring of advanced glycation end prod-
ucts immunohistology. 
*p<0.05 (control vs. alagebrium); 
� p <0.05 (aminoguanidine vs.
alagebrium).
*,�term PD (17). AGE Cross-linking with the matrix component
of capillary basement membrane increases capillary perme-
ability (19, 20). The present findings of increased peritoneal
permeability to small solutes, together with strong positive
staining for AGE in peritoneal tissues, supports the findings
of previous reports.
Aminoguanidine inhibits AGE formation and cross-link-
ing in vivo and in vitro (17). Administration of aminoguani-
dine to rats inhibits diabetes-induced accumulation of AGEs
and abnormal cross-linking of connective tissue proteins in
the arterial wall (8). However, aminoguanidine has a limita-
tion that it cannot cleave and remove preformed AGEs from
tissue. The results of present study support these observations.
AGE cross-link breakers, such as N-phenacylthiazolium
bromide (PTB) and alabebrium (4, 5-Dimethyl-3-[2-oxo2-
phenylethyl]-thiazolium chloride) (ALT-711) have been recent-
ly reported (10-12). Alagebrium is a member of a new gen-
eration of compounds developed for clinical investigation
which can presumably cleave established AGE cross-links.
These cross-link breakers have been shown to reverse AGE-
mediated vascular stiffness in diabetic rats (12) and have
improved arterial compliance in aged humans (13). Many
studies have reported the effectiveness of alagebrium in a
variety of diabetic associated disease models (14-16). In the
present study, alagebrium reduced preformed AGEs in cap-
illaries and mesothelial cells in the parietal peritoneum, and
improved peritoneal permeability to small solutes, after long-
term peritoneal dialysis using high glucose solutions. The
present findings of breakdown of preformed peritoneal AGE
and prevention of increased peritoneal permeability, observed
after long-term peritoneal dialysis using high glucose solu-
tions containing alagebrium, suggest that AGE accumula-
tion in the peritoneum and in the vascular walls resulted in
increased capillary permeability to small solutes.
Loss of ultrafiltration is typically associated with increased
permeability to small solutes such as creatinine (18). These
observations could be explained by AGE accumulation in
the peritoneal membrane, resulting in increased permeabili-
ty to solutes. This might occur via vascular effects or base-
ment membrane thickening, analogous to the situation in
diabetes (19). AGE modification of collagen in submesothe-
lial interstitium might diminish the diffusion resistance to
small solutes and account for a more pronounced increase in
permeability to small solutes than to macromolecules (20).
Alternatively, the increased expression of RAGE secondary
to AGE accumulation may result in alteration of the matrix
components of the vascular walls thus modifying their per-
meability. In the present study, rats dialyzed with high glu-
cose solution had significantly higher permeability to small
solutes compared with rats dialyzed with high glucose solu-
tion containing alagebrium. Cross-linking of basement mem-
brane matrix proteins by AGEs such as laminin, heparin
sulfate proteoglycan or type IV collagen disturbs the integri-
ty of basement membrane (21, 22), which increases vascular
permeability. Expression of RAGE on the vascular endothe-
lium induces an increase in permeability of vascular wall
(23). In the present study, AGE staining was evident in the
vascular walls of the rats. Accordingly, the accumulation of
AGE in the vascular walls of these rats appears to correlate
with the increased peritoneal permeability.
Monitoring changes in body weight over time is a useful
way of assessing the general condition of experimental rats.
Our rats gained weight throughout the study. All rats were
dialyzed with high glucose solutions and therefore there were
no significant difference in body weights between groups.
The limitation of this study is that there was not a negative
control group-rats that do not receive intraperitoneal injec-
tion of high glucose solution-in experimental design. So it
was hard to compare group I with negative control group.
In order to compare the effects of glucose based solutions
with those of non-glucose based solutions-specifically, AGE
formation in the peritoneal membrane and subsequent effects
on peritoneal transport characteristics, a negative control
group is necessarily needed. However, this study was to eval-
uate and compare the ability to cleave preformed peritoneal
AGE of aminoguanidine to those of alagebrium with respect
to peritoneal transport characteristics and AGE. Thus group
I was designed as control group.
In conclusion, the present study demonstrated that int-
raperitoneal alagebrium could reduce preformed peritoneal
AGE and could improve peritoneal permeability in an ani-
mal model of long-term peritoneal dialysis. These results
suggest that cross link breaker, alagebrium offered a benefi-
cial therapeutic approach when compared with inhibitors of
AGE formation, in rats treated with peritoneal dialysis.
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